Alto Neuroscience ANRO Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's other commercial liabilities?
- Alto Neuroscience (ANRO) reported other commercial liabilities of $7.61M in Q1 2026.
- How has Alto Neuroscience's other commercial liabilities changed year-over-year?
- Alto Neuroscience's other commercial liabilities increased by 29.6% year-over-year, from $5.87M to $7.61M.
- What is the long-term trend for Alto Neuroscience's other commercial liabilities?
- Over 2 years (2023 to 2025), Alto Neuroscience's other commercial liabilities has grown at a 39.8% compound annual growth rate (CAGR), from $4.54M to $8.86M.